Podcast TCTMD Talking Points The XIENCE 90/28 Trial Roxana Mehran and C. Michael Gibson discuss 3-month and 1-month DAPT after everolimus-eluting stents in high-bleeding-risk patients.
Podcast TCTMD Talking Points The MSTOPS Trial Steven Steinhubl and C. Michael Gibson discuss 3-year outcomes in a nationwide, randomized, pragmatic clinical trial of A-fib screening.
Podcast TCTMD Talking Points The TARGET FFR Trial Damien Collison and C. Michael Gibson discuss a randomized trial of physiology-guided PCI optimization.
Podcast TCTMD Talking Points The STRENGTH Trial A. Michael Lincoff and C. Michael Gibson discuss CV outcomes with omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia.
Podcast TCTMD Talking Points The OPTIMIZE Trial Dean Kereiakes and C. MIchael Gibson discuss a randomized trial of a novel, ultra-low-profile fixed-wire DES.
Podcast TCTMD Talking Points The AHA COVID-19 CVD Registry Robert Harrington and C. Michael Gibson discuss the registry's design, implementation, and initial results.
Podcast TCTMD Talking Points The TANGO Trial Ehrin Armstrong and C. Michael Gibson discuss a randomized, dose-escalation trial of temsirolimus adventitial delivery below the knee.
Podcast TCTMD Talking Points The GALACTIC-HF Trial John Teerlink and C. Michael Gibson discuss omecamtiv mecarbil in chronic HFrEF.
Podcast TCTMD Talking Points The NACMI COVID-19 Registry Timothy Henry and C. Michael Gibson discuss outcomes from the North American registry.
Podcast TCTMD Talking Points The EXPLORER-HCM Trial Iacopo Olivotto and C. Michael Gibson discuss mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy.